QuidelOrtho (NASDAQ:QDEL) Shares Down 6.5% – Should You Sell?

QuidelOrtho Corporation (NASDAQ:QDEL)’s share price was down 6.5% during trading on Tuesday . The company traded as low as $17.03 and last traded at $17.05. Approximately 125,249 shares changed hands during trading, a decline of 93% from the average session volume of 1,860,770 shares. The stock had previously closed at $18.23.

Analyst Ratings Changes

QDEL has been the subject of a number of recent analyst reports. Zacks Research upgraded QuidelOrtho from a “strong sell” rating to a “hold” rating in a research report on Monday, June 15th. Jefferies Financial Group restated a “hold” rating on shares of QuidelOrtho in a research report on Monday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research note on Tuesday, April 21st. Citigroup cut their price objective on shares of QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Finally, Wall Street Zen upgraded shares of QuidelOrtho from a “sell” rating to a “hold” rating in a research note on Sunday. Four investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $14.88.

QuidelOrtho Stock Down 3.6%

The firm has a 50 day simple moving average of $12.61 and a two-hundred day simple moving average of $20.19. The stock has a market capitalization of $1.20 billion, a P/E ratio of -0.99 and a beta of 0.77. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33.

QuidelOrtho (NASDAQ:QDEL) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The business had revenue of $619.80 million during the quarter, compared to the consensus estimate of $665.23 million. During the same quarter in the previous year, the business posted $0.74 EPS. The company’s revenue for the quarter was down 10.5% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, equities research analysts expect that QuidelOrtho Corporation will post 1.83 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of QDEL. Aristotle Capital Boston LLC grew its holdings in shares of QuidelOrtho by 62.4% during the 3rd quarter. Aristotle Capital Boston LLC now owns 382,389 shares of the company’s stock valued at $11,261,000 after purchasing an additional 146,956 shares during the last quarter. American Century Companies Inc. lifted its stake in QuidelOrtho by 10.4% in the 3rd quarter. American Century Companies Inc. now owns 2,115,557 shares of the company’s stock valued at $62,303,000 after purchasing an additional 199,909 shares during the last quarter. Tejara Capital Ltd lifted its stake in QuidelOrtho by 97.2% in the 4th quarter. Tejara Capital Ltd now owns 208,327 shares of the company’s stock valued at $5,950,000 after purchasing an additional 102,700 shares during the last quarter. Phocas Financial Corp. boosted its position in QuidelOrtho by 45.7% in the fourth quarter. Phocas Financial Corp. now owns 170,018 shares of the company’s stock valued at $4,856,000 after buying an additional 53,353 shares in the last quarter. Finally, Rice Hall James & Associates LLC boosted its position in QuidelOrtho by 222.0% in the fourth quarter. Rice Hall James & Associates LLC now owns 833,791 shares of the company’s stock valued at $23,813,000 after buying an additional 574,877 shares in the last quarter. Institutional investors and hedge funds own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.